Literature DB >> 32535079

Artemisinin attenuates early renal damage on diabetic nephropathy rats through suppressing TGF-β1 regulator and activating the Nrf2 signaling pathway.

Haishan Zhang1, Simin Qi2, Yongchun Song3, Cheng Ling4.   

Abstract

AIM: The present study aims to investigate the protective effects of artemisinin (ATZ) on early renal damage in experimental diabetic rats and its probable mechanism.
METHODS: Models of diabetic nephropathy (DN) rats was established utilizing streptozotocin (STZ)-injection intraperitoneally (55 mg/kg) method. All rats were subsequently divided into normal control group, model group and ATZ (25, 50, 75 mg/kg) group randomly. Biochemical parameters including body weight, kidney index, blood glucose, 24 h UAER, Scr, BUN, T-SOD, GSH-Px and MDA were comprehensively determined after 8-week consecutive administrations. HE and PAS stainings were performed to observe the histopathological alterations of kidney. Western blot was conducted to detect the expressions of TGF-β1, Nrf2, HQ-1 and NQO1. KEY
FINDINGS: ATZ at three concentrations in ATZ group significantly increased the body weight. Biochemical parameters altered significantly between model group and ATZ group. Moreover, ATZ inhibited TGF-β1 protein expression and activated the Nrf2 signaling pathway. Pathological histology results revealed the alterations including mesangial cells proliferation, thickness of glomerular capillary basement membrane, extracellular matrix (ECM) and the 24 h UAER. Western blot analysis demonstrated the increase of antioxidant proteins HO-1 and NQO1 and Nrf2-related proteins. SIGNIFICANCE: ATZ could reduce early renal oxidative stress damage in DN rats by inhibiting TGF-β1 protein expression in kidney tissues as well as activating the Nrf2 signaling pathway and enhancing the expression of antioxidant proteins, thereby exerting the protective effects on DN kidney. The current study is the first report of ATZ on attenuating effects on kidney of DN rats, which could lay solid theoretical foundations on clinical application of ATZ to treat DN.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Artemisinin; Diabetic nephropathy; HQ-1; NQO1; Nrf2; TGF-β1

Mesh:

Substances:

Year:  2020        PMID: 32535079     DOI: 10.1016/j.lfs.2020.117966

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

Review 1.  Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases.

Authors:  Anne Grunenwald; Lubka T Roumenina; Marie Frimat
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

Review 2.  Pharmacotherapy against Oxidative Stress in Chronic Kidney Disease: Promising Small Molecule Natural Products Targeting Nrf2-HO-1 Signaling.

Authors:  Md Jamal Uddin; Ee Hyun Kim; Md Abdul Hannan; Hunjoo Ha
Journal:  Antioxidants (Basel)       Date:  2021-02-07

Review 3.  Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug.

Authors:  Fatih M Uckun; Saran Saund; Hitesh Windlass; Vuong Trieu
Journal:  Front Pharmacol       Date:  2021-03-19       Impact factor: 5.810

Review 4.  The Potential of Nrf2 Activation as a Therapeutic Target in Systemic Lupus Erythematosus.

Authors:  Michelle T Barati; Dawn J Caster
Journal:  Metabolites       Date:  2022-02-06

Review 5.  Protective Effect and Possible Mechanisms of Artemisinin and Its Derivatives for Diabetic Nephropathy: A Systematic Review and Meta-Analysis in Animal Models.

Authors:  Haoyue Feng; Tingchao Wu; Qi Zhou; Hui Li; Tianyi Liu; Xitao Ma; Rensong Yue
Journal:  Oxid Med Cell Longev       Date:  2022-04-25       Impact factor: 7.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.